FDMT - Company ID 0001650648
The table below shows 4D Molecular Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$68.13M | -$47.76M | -$29.09M | -$27.91M | -$23.55M | -$15.37M |
| Capital expenditure | - | $631.00K | $710.00K | $1.01M | $6.41M | $642.00K |
| Investing cash flow | $68.89M | $31.95M | -$263.26M | $43.13M | -$54.11M | -$642.00K |
| Dividends paid | - | - | - |
4D Molecular Therapeutics, Inc. reported operating cash flow of -$109.08M for fiscal year 2025. That is up 18.9% from -$134.59M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$36.71M (FY 2019) to -$109.08M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $11.48M | $0.00 | $318.83M | $10.99M | $629.00K | -$847.00K |